Does LEVOMILNACIPRAN Cause Mobility decreased? 124 Reports in FDA Database
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
According to the FDA Adverse Event Reporting System (FAERS), 124 reports of Mobility decreased have been filed in association with LEVOMILNACIPRAN (Fetzima). This represents 9.0% of all adverse event reports for LEVOMILNACIPRAN.
124
Reports of Mobility decreased with LEVOMILNACIPRAN
9.0%
of all LEVOMILNACIPRAN reports
124
Deaths
85
Hospitalizations
How Dangerous Is Mobility decreased From LEVOMILNACIPRAN?
Of the 124 reports, 124 (100.0%) resulted in death, 85 (68.5%) required hospitalization, and 86 (69.4%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEVOMILNACIPRAN. However, 124 reports have been filed with the FAERS database.
What Other Side Effects Does LEVOMILNACIPRAN Cause?
Off label use (376)
Drug ineffective (315)
Gastrooesophageal reflux disease (295)
Vomiting (294)
Hypoaesthesia (290)
Abdominal pain upper (285)
Paraesthesia (282)
Memory impairment (277)
Blepharospasm (276)
Taste disorder (276)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which LEVOMILNACIPRAN Alternatives Have Lower Mobility decreased Risk?
LEVOMILNACIPRAN vs LEVONORGESTREL
LEVOMILNACIPRAN vs LEVORPHANOL
LEVOMILNACIPRAN vs LEVOSIMENDAN
LEVOMILNACIPRAN vs LEVOSULPIRIDE
LEVOMILNACIPRAN vs LEVOTHYROXINE